Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001703792 | SCV000523593 | likely benign | not provided | 2020-03-18 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000533047 | SCV000653545 | benign | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 11 | 2024-01-04 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001703792 | SCV004126140 | likely benign | not provided | 2022-09-01 | criteria provided, single submitter | clinical testing | B3GALNT2: BP4, BP7 |
Breakthrough Genomics, |
RCV001703792 | SCV005264381 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Prevention |
RCV004745376 | SCV005352292 | likely benign | B3GALNT2-related disorder | 2024-08-14 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |